ArticleFrontiers in endocrinology2025
Epidemiological research on diabetic nephropathy at global, regional, and national levels from 1990 to 2021: an analysis derived from the global burden of disease 2021 study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of rutin on renal function, oxidative stress and fibrosis in animal models of diabetic nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Reappraising Kidney Biopsy in Diabetic Kidney Disease: Histopathology, Clinical Course, and the Future of Precision Nephrology.Journal of clinical medicine · 2026Review
- Advances in understanding the NLRP3 inflammasome‑mediated mechanisms and therapeutic targets in diabetic nephropathy (Review).International journal of molecular medicine · 2026Review
- Spectrum of biopsy-proven kidney diseases in 3514 patients at a single center in Northwest China from 2014 to 2023.Clinical and experimental nephrology · 2026Article
- Ferroptosis-related proteins ALOX15 and HMOX1 are upregulated and associated with inflammation in patients with diabetic nephropathy: a prospective cross-sectional study.International urology and nephrology · 2026Article
- Burden of chronic kidney disease due to type 2 diabetes mellitus in Asia: A retrospective analysis.Medicine · 2026Article
- Quality and reliability of diabetic nephropathy-related videos on TikTok and Bilibili: A cross-sectional content analysis.Medicine · 2026Article
- The Role and Therapeutic Potential of the STING Signaling Pathway in the Pathogenesis of Diabetic Nephropathy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Associations of MALAT1 rs619586/rs3200401 and ANRIL rs10965215/rs10738605 polymorphisms with type 2 diabetes and diabetic nephropathy risk in an Egyptian population.Frontiers in endocrinology · 2026Article
- Role of metabolic reprogramming and lactylation in diabetic nephropathy: molecular mechanisms and therapeutic prospects - a narrative review.Frontiers in endocrinology · 2026Review
- Hydroxysafflor Yellow A improves diabetic nephropathy by inhibiting PI3K/AKT/mTOR pathway based on a multidimensional study.Frontiers in medicine · 2026Article
- Focusing on the Apolipoprotein M-Mitophagy Axis: A Mechanism for Renal Protection in Diabetic Nephropathy.Journal of diabetes research · 2026Review
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
- Diabetes: A Subspecialty of Medicine and a Matter of Public Health.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A comprehensive assessment of the disease burden is essential for developing effective strategies to address diabetic nephropathy. This study investigates the long-term global trends and epidemiological characteristics of diabetic nephropathy. Methods: Data on diabetic nephropathy from the Global Burden of Disease (GBD) 2021 were utilized to evaluate morbidity, mortality, disability-adjusted life years (DALYs), and the impact of the Socio-Demographic Index (SDI). Global risk attribution was assessed, and the Bayesian Age-Period-Cohort (BAPC) model was applied to forecast the future burden of diabetic nephropathy. Results: In 2021, there were 107.6 million prevalent cases of diabetic nephropathy globally (95% UI: 99.2-116.0), with an age-standardized prevalence rate of 1,259.6 per 100,000 population (95% UI: 1,162.0-1,359.9), representing a 5.1% decline since 1990. Global deaths attributed to diabetic nephropathy in 2021 reached 477.3 thousand (95% UI: 401.5-566.0), with an age-standardized mortality rate of 5.7 per 100,000 (95% UI: 4.8-6.8), reflecting a 37.8% increase since 1990. The number of DALYs attributable to diabetic nephropathy was 11,278.9 thousand (95% UI: 9,682.8-13,103.9), with an age-standardized DALY rate of 131.1 per 100,000 (95% UI: 112.8-152.5), indicating a 24% rise since 1990. Conclusions: Over the past three decades, the global age-standardized prevalence of diabetic nephropathy has declined, while age-standardized mortality and DALY rates have increased. Significant disparities exist in prevalence, incidence, and DALY rates across regions and countries. The SDI exerts a notable influence on diabetic nephropathy prevalence, underscoring the importance of sustained and enhanced management of risk factors to prevent and treat this condition. Diabetic nephropathy remains a critical global health challenge moving forward.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.